CHUGAI PHARMACEUTICAL CO., LTD.

Print

Information Meeting on TECENTRIQ®

Date April 12, 2018
Presentations
1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center
3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan

[ PDF 9.5MB]

  Webcasts (Japanese/ English)
  To view the webcasts, please visit the websites below.

Japanese : http://www.c-hotline.net/Viewer/Default/CHPH17cccb45b0dfb2e695bf20c79dd859b7

English : http://www.c-hotline.net/Viewer/Default/CHPH834d9014c8997c83937a528ac0d16c68

To view PDF files,
you will need Adobe® Reader® which is available as a free download.

Close